Pyrexia Management in Patients with Melanoma Treated with Dabrafenib/Trametinib Combination Therapy
The Journey Through Stage III Melanoma: A Guide for Patients - CONQUER: the patient voice
Cancer Trial Results
Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content. - ppt download
COMBI-AD Trial 5-Year Analysis Data
Un anno di targeted therapy nel melanoma - OncoInfo
Pyrexia Management in Patients with Melanoma Treated with Dabrafenib/Trametinib Combination Therapy
ASCO 2022: Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III BRAFV600-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD.
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
Présentation PowerPoint
Combination targeted adjuvant therapy doubles relapse-free survival in stage III melanoma | VJOncology
Adjuvant Therapy for Melanoma Efficacy | TAFINLAR + MEKINIST
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma | NEJM
PDF) Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma
COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF V600–mutant melanoma on Vimeo
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial - The Lancet Oncology
Adjuvant Dabrafenib/Trametinib in Patients With Stage III Melanoma and BRAF V600 Mutations - The ASCO Post
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma | NEJM
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.,The Lancet Oncology - X-MOL
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial - The Lancet Oncology
Pyrexia Management in Patients with Melanoma Treated with Dabrafenib/Trametinib Combination Therapy
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma | NEJM
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma | NEJM
Summarized Outcome Data for Adjuvant Therapy Trials | Download Scientific Diagram
Neoadyuvancia y Adyuvancia en melanoma - ppt download
